Compounds of the formula I: ##STR00001##
or pharmaceutically acceptable salts thereof,
wherein m, p, q, Ar, R.sup.1 and R.sup.2 are as defined herein. Also provided are methods for preparing, compositions comprising, and methods for using compounds of formula I.

Compounds of the formula I: ##STR00001##
or pharmaceutically acceptable salts thereof,
wherein m, p, q, Ar, R.sup.1 and R.sup.2 are as defined herein. Also provided are methods for preparing, compositions comprising, and methods for using compounds of formula I.

Inhibitor compounds and agents of Cathepsin C, CELA1, CELA3A and/or structurally related molecules thereto, compositions comprising same and uses thereof in the inhibition and/or prevention of cell and/or tissue necrosis is described. Various applications for the described compounds, and combination therapies are described as well.

Inhibitor compounds and agents of Cathepsin C, CELA1, CELA3A and/or structurally related molecules thereto, compositions comprising same and uses thereof in the inhibition and/or prevention of cell and/or tissue necrosis is described. Various applications for the described compounds, and combination therapies are described as well.

A compound of formula (I) is: ##STR00001##
wherein: X.sup.2 represents a CONR.sub.k group, a NR.sub.kCO group, a O group, a CO group, a SO.sub.2-group, a CSNH group, a CH.sub.2NH, a ##STR00002##
group, or a heterocyclyl, wherein the heterocyclyl is a 5- or 6-membered ring comprising 1, 2, 3 or 4 heteroatoms selected from O, S and/or N; Y.sup.2 represents a hydrogen atom, a halogen atom, a hydroxyl group, a morpholinyl group, optionally substituted by a (C.sub.1-C.sub.4)alkyl group or a trifluoromethyl group, a bridged morpholinyl group, a (C.sub.5-C.sub.11)bicycloalkyl group, an adamantyl group, a piperidinyl group, a (C.sub.1-C.sub.4)alkenyl group, a PO(OR.sub.a)(OR.sub.b) group, a 5-membered heteroaromatic ring or a CR.sup.1R.sup.2R.sup.3 group, or any of its pharmaceutically acceptable salt.

A compound of formula (I) is: ##STR00001##
wherein: X.sup.2 represents a CONR.sub.k group, a NR.sub.kCO group, a O group, a CO group, a SO.sub.2-group, a CSNH group, a CH.sub.2NH, a ##STR00002##
group, or a heterocyclyl, wherein the heterocyclyl is a 5- or 6-membered ring comprising 1, 2, 3 or 4 heteroatoms selected from O, S and/or N; Y.sup.2 represents a hydrogen atom, a halogen atom, a hydroxyl group, a morpholinyl group, optionally substituted by a (C.sub.1-C.sub.4)alkyl group or a trifluoromethyl group, a bridged morpholinyl group, a (C.sub.5-C.sub.11)bicycloalkyl group, an adamantyl group, a piperidinyl group, a (C.sub.1-C.sub.4)alkenyl group, a PO(OR.sub.a)(OR.sub.b) group, a 5-membered heteroaromatic ring or a CR.sup.1R.sup.2R.sup.3 group, or any of its pharmaceutically acceptable salt.